Does the media refer more to BVS or TLSI?

In the previous week, TriSalus Life Sciences had 4 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for TriSalus Life Sciences and 1 mentions for Bioventus. TriSalus Life Sciences' average media sentiment score of 0.05 beat Bioventus' score of -0.50 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TLSI or CBLL?

In the previous week, TriSalus Life Sciences had 2 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for TriSalus Life Sciences and 3 mentions for CeriBell. CeriBell's average media sentiment score of 0.81 beat TriSalus Life Sciences' score of 0.05 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SGP or TLSI?

Spyglass Pharma has higher earnings, but lower revenue than TriSalus Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A TriSalus Life Sciences $45.15M 4.37 -$39.23M -$1.41 N/A

Is SGP or TLSI more profitable?

Spyglass Pharma has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A N/A N/A TriSalus Life Sciences -60.85% N/A -69.91%

Does the media refer more to SGP or TLSI?

In the previous week, Spyglass Pharma had 2 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for Spyglass Pharma and 5 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.05 beat Spyglass Pharma's score of -0.04 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyglass Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLSI or SIBN?

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 5 articles in the media. SiBone's average media sentiment score of 0.11 beat TriSalus Life Sciences' score of 0.05 indicating that SiBone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SiBone 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BBNX or TLSI?

In the previous week, Beta Bionics had 15 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 20 mentions for Beta Bionics and 5 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.05 beat Beta Bionics' score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beta Bionics 5 Very Positive mention(s) 0 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TriSalus Life Sciences (TLSI) Competitors

$3.21 +0.04 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 +0.01 (+0.31%)

As of 04:10 PM Eastern

Compare

TLSI vs. BVS, CBLL, SGP, SIBN, and BBNX

Should you buy TriSalus Life Sciences stock or one of its competitors? MarketBeat compares TriSalus Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TriSalus Life Sciences include Bioventus (BVS), CeriBell (CBLL), Spyglass Pharma (SGP), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does TriSalus Life Sciences compare to Bioventus?

Bioventus (NASDAQ:BVS) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk, institutional ownership and media sentiment.

Bioventus has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Bioventus has a net margin of 4.94% compared to TriSalus Life Sciences' net margin of -60.85%. Bioventus' return on equity of 29.97% beat TriSalus Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

Bioventus has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.32	$22.73M	$0.41	21.83
TriSalus Life Sciences	$45.15M	4.37	-$39.23M	-$1.41	N/A

Bioventus currently has a consensus price target of $14.00, indicating a potential upside of 56.42%. TriSalus Life Sciences has a consensus price target of $7.50, indicating a potential upside of 133.64%. Given TriSalus Life Sciences' higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

62.9% of Bioventus shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 33.0% of Bioventus shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, TriSalus Life Sciences had 4 more articles in the media than Bioventus. MarketBeat recorded 5 mentions for TriSalus Life Sciences and 1 mentions for Bioventus. TriSalus Life Sciences' average media sentiment score of 0.05 beat Bioventus' score of -0.50 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bioventus beats TriSalus Life Sciences on 13 of the 17 factors compared between the two stocks.

How does TriSalus Life Sciences compare to CeriBell?

TriSalus Life Sciences (NASDAQ:TLSI) and CeriBell (NASDAQ:CBLL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 133.64%. CeriBell has a consensus target price of $22.20, indicating a potential upside of 22.38%. Given TriSalus Life Sciences' higher possible upside, research analysts clearly believe TriSalus Life Sciences is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

TriSalus Life Sciences has a net margin of -60.85% compared to CeriBell's net margin of -63.51%. TriSalus Life Sciences' return on equity of 0.00% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
CeriBell	-63.51%	-38.19%	-30.92%

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 20.1% of CeriBell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TriSalus Life Sciences has higher earnings, but lower revenue than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	4.37	-$39.23M	-$1.41	N/A
CeriBell	$95.07M	7.24	-$53.41M	-$1.63	N/A

In the previous week, TriSalus Life Sciences had 2 more articles in the media than CeriBell. MarketBeat recorded 5 mentions for TriSalus Life Sciences and 3 mentions for CeriBell. CeriBell's average media sentiment score of 0.81 beat TriSalus Life Sciences' score of 0.05 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market.

Summary

CeriBell beats TriSalus Life Sciences on 9 of the 17 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Spyglass Pharma has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
TriSalus Life Sciences	-60.85%	N/A	-69.91%

Spyglass Pharma has higher earnings, but lower revenue than TriSalus Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
TriSalus Life Sciences	$45.15M	4.37	-$39.23M	-$1.41	N/A

2.6% of TriSalus Life Sciences shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Spyglass Pharma had 2 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for Spyglass Pharma and 5 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.05 beat Spyglass Pharma's score of -0.04 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyglass Pharma presently has a consensus price target of $45.00, indicating a potential upside of 140.13%. TriSalus Life Sciences has a consensus price target of $7.50, indicating a potential upside of 133.64%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Spyglass Pharma beats TriSalus Life Sciences on 6 of the 10 factors compared between the two stocks.

How does TriSalus Life Sciences compare to SiBone?

TriSalus Life Sciences (NASDAQ:TLSI) and SiBone (NASDAQ:SIBN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

TriSalus Life Sciences has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, SiBone has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

TriSalus Life Sciences currently has a consensus target price of $7.50, indicating a potential upside of 133.64%. SiBone has a consensus target price of $23.00, indicating a potential upside of 53.64%. Given TriSalus Life Sciences' higher possible upside, research analysts plainly believe TriSalus Life Sciences is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

SiBone has a net margin of -8.10% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat SiBone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
SiBone	-8.10%	-9.56%	-7.06%

SiBone has higher revenue and earnings than TriSalus Life Sciences. SiBone is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	4.37	-$39.23M	-$1.41	N/A
SiBone	$206.22M	3.22	-$18.90M	-$0.39	N/A

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 5 articles in the media. SiBone's average media sentiment score of 0.11 beat TriSalus Life Sciences' score of 0.05 indicating that SiBone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
SiBone	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 98.1% of SiBone shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by insiders. Comparatively, 4.0% of SiBone shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

SiBone beats TriSalus Life Sciences on 10 of the 15 factors compared between the two stocks.

How does TriSalus Life Sciences compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

TriSalus Life Sciences has lower revenue, but higher earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$110.24M	5.61	-$73.20M	-$1.51	N/A
TriSalus Life Sciences	$45.15M	4.37	-$39.23M	-$1.41	N/A

In the previous week, Beta Bionics had 15 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 20 mentions for Beta Bionics and 5 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.05 beat Beta Bionics' score of 0.00 indicating that TriSalus Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	5 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TriSalus Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Beta Bionics has a beta of 3.4, meaning that its share price is 240% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Beta Bionics currently has a consensus price target of $19.70, suggesting a potential upside of 42.03%. TriSalus Life Sciences has a consensus price target of $7.50, suggesting a potential upside of 133.64%. Given TriSalus Life Sciences' higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

2.6% of TriSalus Life Sciences shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Beta Bionics has a net margin of -60.27% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
TriSalus Life Sciences	-60.85%	N/A	-69.91%

Summary

Beta Bionics beats TriSalus Life Sciences on 9 of the 17 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TLSI vs. The Competition

Export

Metric	TriSalus Life Sciences	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$197.16M	$8.28B	$6.43B	$12.05B
Dividend Yield	N/A	2.52%	2.67%	5.56%
P/E Ratio	-2.28	16.16	23.75	23.75
Price / Sales	4.37	6.49	479.79	84.65
Price / Cash	N/A	17.45	26.99	37.25
Price / Book	-4.72	3.55	10.28	6.78
Net Income	-$39.23M	$225.32M	$3.57B	$337.51M
7 Day Performance	-12.53%	-1.06%	-1.45%	-2.72%
1 Month Performance	-27.54%	2.22%	3.25%	1.87%
1 Year Performance	-40.45%	-3.10%	23.34%	26.60%

TriSalus Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TLSI TriSalus Life Sciences	3.6883 of 5 stars	$3.21 +1.3%	$7.50 +133.6%	-41.2%	$197.16M	$45.15M	N/A	106
BVS Bioventus	3.9641 of 5 stars	$8.41 +3.7%	$14.00 +66.5%	N/A	$703.41M	$568.09M	20.54	1,200	High Trading Volume
CBLL CeriBell	2.3408 of 5 stars	$17.23 -1.5%	$22.20 +28.8%	+2.0%	$657.54M	$89.06M	N/A	N/A	News Coverage
SGP Spyglass Pharma	N/A	$18.75 +2.1%	$45.00 +140.0%	N/A	$624.90M	N/A	N/A	65
SIBN SiBone	2.5753 of 5 stars	$13.85 -1.2%	$23.00 +66.1%	-20.0%	$613.80M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TLSI) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. BVS, CBLL, SGP, SIBN, and BBNX

How does TriSalus Life Sciences compare to Bioventus?

Summary

How does TriSalus Life Sciences compare to CeriBell?

Summary

How does TriSalus Life Sciences compare to Spyglass Pharma?

Summary

How does TriSalus Life Sciences compare to SiBone?

Summary

How does TriSalus Life Sciences compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TriSalus Life Sciences (TLSI) Competitors

TLSI vs. BVS, CBLL, SGP, SIBN, and BBNX

How does TriSalus Life Sciences compare to Bioventus?

Which has more volatility and risk, BVS or TLSI?

Is BVS or TLSI more profitable?

Which has preferable earnings & valuation, BVS or TLSI?

Do analysts rate BVS or TLSI?

Do insiders & institutionals have more ownership in BVS or TLSI?

Does the media refer more to BVS or TLSI?

Summary

How does TriSalus Life Sciences compare to CeriBell?

Do analysts rate TLSI or CBLL?

Is TLSI or CBLL more profitable?

Do insiders and institutionals believe in TLSI or CBLL?

Which has preferable earnings & valuation, TLSI or CBLL?

Does the media prefer TLSI or CBLL?

Which has more risk & volatility, TLSI or CBLL?

Summary

How does TriSalus Life Sciences compare to Spyglass Pharma?

Is SGP or TLSI more profitable?

Which has stronger valuation & earnings, SGP or TLSI?

Do institutionals & insiders believe in SGP or TLSI?

Does the media refer more to SGP or TLSI?

Do analysts rate SGP or TLSI?

Summary

How does TriSalus Life Sciences compare to SiBone?

Which has more volatility and risk, TLSI or SIBN?

Do analysts rate TLSI or SIBN?

Is TLSI or SIBN more profitable?

Which has preferable valuation and earnings, TLSI or SIBN?

Does the media refer more to TLSI or SIBN?

Do insiders & institutionals have more ownership in TLSI or SIBN?

Summary

How does TriSalus Life Sciences compare to Beta Bionics?

Which has better valuation and earnings, BBNX or TLSI?

Does the media favor BBNX or TLSI?

Which has more volatility and risk, BBNX or TLSI?

Do analysts rate BBNX or TLSI?

Do insiders & institutionals hold more shares of BBNX or TLSI?

Is BBNX or TLSI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLSI vs. The Competition

TriSalus Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools